JP Patent

JP7558216B2 — Ｆｇｆｒ阻害剤による治療に応答性であるがん患者を同定する際の、ｆｇｆｒ変異遺伝子パネルの使用

Assigned to ヤンセン ファーマシューティカ エヌ．ベー． · Expires 2024-09-30 · 2y expired

What this patent protects

Patent listed against Balversa.

Drugs covered by this patent

Patent Metadata

Patent number
JP7558216B2
Jurisdiction
JP
Classification
—
Expires
2024-09-30
Drug substance claim
No
Drug product claim
No
Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.